>> At the end of the day, I think it is as phenomenal opportunity just to be able
to influence a process to where thousands of patients' lives are being changed,
and that's ultimately what motivates me, and working on programs in which millions
of patients' lives will be changed based on advancing the science that we have
and being able to truly make a difference, again, across various sectors.
I would say the biggest challenge right now that's not one in which is necessarily personal
to me, but I think overall as industry, I think there's a lot of rhetoric right now with respect
to drug pricing, and I think folks really don't have a full understanding
of really what it takes to bring a product to market.
And so the onus is on us as industry to continue to educate folks on our business
and how we invest in terms of research, and the dollars that are spent,
and the outcomes that are achieved so that folks can have more of an informed opinion
about what they think is an excessive price versus not so excessive and understanding that,
you know, only a few molecules make it.
And so if you're a company that has a strong research and development organization,
that's a considerable investment that goes back, and I'm fortunate enough to work
with an organization that invests roughly 20 percent of the revenue back
into research, and discovery, and development.
And so that's one in which I'm proud of, but it's one in which we still have
to do a better job of clearly articulating, you know,
why our medicines are priced the way they are.